Passage Bio, Inc.PASGNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank61
5Y CAGR-15.1%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-15.1%/yr
Long-term compound
Percentile
P61
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 13.20% |
| Q3 2025 | -3.81% |
| Q2 2025 | -25.72% |
| Q1 2025 | 52.39% |
| Q4 2024 | -44.93% |
| Q3 2024 | 11.38% |
| Q2 2024 | -0.08% |
| Q1 2024 | 3.66% |
| Q4 2023 | -23.20% |
| Q3 2023 | 1.49% |
| Q2 2023 | 4.09% |
| Q1 2023 | 14.14% |
| Q4 2022 | -36.36% |
| Q3 2022 | -17.91% |
| Q2 2022 | -13.96% |
| Q1 2022 | -12.17% |
| Q4 2021 | 14.78% |
| Q3 2021 | -2.88% |
| Q2 2021 | 23.73% |
| Q1 2021 | 23.11% |
| Q4 2020 | 29.91% |
| Q3 2020 | 5.28% |
| Q2 2020 | 54.37% |
| Q1 2020 | 32.46% |
| Q4 2019 | 199.42% |
| Q3 2019 | 24.90% |
| Q2 2019 | -16.12% |
| Q1 2019 | 139.92% |
| Q4 2018 | 0.00% |